Innately Innovative: IFM Therapeutics Acquired By BMS
Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Bruce Booth, Contributor Tags: NYSE:BMY Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Mergers and Aquisitions | Pharmaceuticals